Could a cholesterol drug boost lung cancer immunotherapy?
NCT ID NCT05144529
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This study looked at adding evolocumab (a cholesterol-lowering drug) to standard immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer who had not received prior treatment. The goal was to see if the combination was safe and could improve the immune system's ability to fight cancer. The study was terminated early and enrolled 19 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Univ. Medical Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.